Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov;53(11):1379-1389.
doi: 10.1038/s41409-018-0171-z. Epub 2018 Apr 18.

Epidemiology and biology of relapse after stem cell transplantation

Mary Horowitz  1 , Hans Schreiber  2 , Alex Elder  3 , Olaf Heidenreich  3 , Josef Vormoor  3   4 , Christina Toffalori  5 , Luca Vago  5   6 , Nicolaus Kröger  7
Affiliations
Review

Epidemiology and biology of relapse after stem cell transplantation

Mary Horowitz et al. Bone Marrow Transplant. 2018 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None of the authors declared any conflict of interests.

Figures

Figure 1.
Figure 1.
Causes of death among patients transplanted for malignancy in 2012–2013 (Data from the Center for International Blood and Marrow Transplant Research).
Figure 2A-B.
Figure 2A-B.
Five-year outcomes after allogeneic hematopoietic stem cell transplantations for hematologic malignancy by decade (Data from the Center for International Blood and Marrow Transplant Research). (A) Five-year outcomes (in percents) after autologous hematopoietic stem cell transplantations for hematologic malignancy by decade (Data from the Center for International Blood and Marrow Transplant Research). (B)
Figure 2A-B.
Figure 2A-B.
Five-year outcomes after allogeneic hematopoietic stem cell transplantations for hematologic malignancy by decade (Data from the Center for International Blood and Marrow Transplant Research). (A) Five-year outcomes (in percents) after autologous hematopoietic stem cell transplantations for hematologic malignancy by decade (Data from the Center for International Blood and Marrow Transplant Research). (B)
Figure 3A-B.
Figure 3A-B.
Five-year outcomes (in percents) after allogeneic hematopoietic stem cell transplantations for acute myeloid leukemia in first complete remission using myeloablative conditioning in patients aged 20–45 years, by decade (Data from the Center for International Blood and Marrow Transplant Research). (A) Five-year outcomes (in percents) after autologous hematopoietic stem cell transplantations for chemosensitive non-Hodgkin lymphoma in patients aged 20–45 years, by decade (Data from the Center for International Blood and Marrow Transplant Research). (B)
Figure 3A-B.
Figure 3A-B.
Five-year outcomes (in percents) after allogeneic hematopoietic stem cell transplantations for acute myeloid leukemia in first complete remission using myeloablative conditioning in patients aged 20–45 years, by decade (Data from the Center for International Blood and Marrow Transplant Research). (A) Five-year outcomes (in percents) after autologous hematopoietic stem cell transplantations for chemosensitive non-Hodgkin lymphoma in patients aged 20–45 years, by decade (Data from the Center for International Blood and Marrow Transplant Research). (B)
Figure 4.
Figure 4.
Loss of mismatched HLA in leukemic cells after haploidentical HSCT. Schematic model of the causes and consequences of genomic loss of the patient-specific HLA haplotype at relapse after transplantation. Leukemic cells, heterozygous at diagnosis for the shared (in blue) and the mismatched patient-specific (in red) haplotype, are exposed to an intense immunological pressure after transplantation, mostly mediated by donor T cells expressing alloreactive T cell receptors (in green) and targeted against the mismatched HLA haplotype. This selective environment favors the emergence of mutant variants that lack the patient-specific HLA haplotype, and are therefore no longer recognized by donor T lymphocytes.
See this image and copyright information in PMC

References

    1. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. The Lancet Haematol 2015; 2(3):e91–e100. doi:10.1016/S2352-3026(15)00028-9. Epub 2015 Mar 1. - DOI - PubMed
    1. Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Societa for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant 2017; 52: 811–817. - PMC - PubMed
    1. D’Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 2017; 23: 1417–1421. - PMC - PubMed
    1. Rafii H, Ruggeri A, Volt F, Brunstein CG, Carreras J, Eapen M, et al. Changing trends of unrelated umbilical cord blood transplantation for hematologic diseases in patients older than fifty years: A Eurocord-Center for International Blood and Marrow Transplant research survey. Biol Blood Marrow Transplant 2016; 22: 1717–1720. - PubMed
    1. Costa LJ, Zhang M-J, Zhong X, Dispenzieri A, Lonial S, Krishnan A et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 1615–1624. - PMC - PubMed

Publication types